Cambridge Commercial Property Market

Executive Summary

Cambridge is the highest-value commercial property market in the UK outside central London, and the only regional market where prime lab and office stock trades at yields tighter than the wider London regional average. HM Land Registry records 890 commercial-leaning transactions across the local authority area in the rolling five-year window to Q1 2026. Volume is small by national standards (the city's local authority area is geographically compact), but the median commercial transaction price of £390,000 is the highest of any Tier 1 city in this set and reflects the structural premium Cambridge commands.

Three features distinguish Cambridge in Q2 2026. First, the Cambridge cluster is the UK's leading life sciences, biotech and deep-tech ecosystem, with AstraZeneca's global HQ at the Cambridge Biomedical Campus, the Babraham Research Campus, Granta Park and the Cambridge Science Park all operating at the institutional end of UK commercial real estate. Lab and life sciences office stock trades at yields tighter than equivalent product anywhere in the country outside the Golden Triangle. Second, the Cambridge South Station opening in 2025 transformed connectivity to the Biomedical Campus and substantially improved capital values across the southern fringe. Third, Cambridge's structural constraint is supply, the Green Belt and planning restrictions limit ground-up delivery, so refurbishment, extension and conversion plays dominate the value-add pipeline.

For a commercial mortgage borrower, Cambridge offers terms close to outer London on prime, with a deeper lender panel than most regional centres reflecting the institutional weight of the occupier base. Mid-market deal flow is dominated by SPV-acquired residential investment at materially higher capital values than peer regional cities.

Transaction activity

The 890 commercial-leaning transactions over the last 60 months break across two distinct populations within HM Land Registry data.

The first is the genuinely commercial freehold subset, properties registered with Property Type O (Other), capturing freehold sales of offices, retail units, industrial premises, lab buildings and other non-residential commercial property. Cambridge accounts for around 200 to 250 such transactions in the window, with a high proportion of office and life-sciences freehold reflecting the depth of the cluster.

The second is the corporate-acquired residential subset, Land Registry PPD Category B sales capturing transfers to non-private individuals. Cambridge accounts for the majority of the 890 figure here, with SPV and limited-company purchases concentrated in central flats (the Eddington development, the wider central area), terraces and semis across Romsey, Mill Road and the eastern suburbs, and the student-let and visiting-academic markets around the University of Cambridge colleges.

Median commercial transaction price across the full subset sits at £390,000, second only to Reading (£335,000) and Oxford (£395,000) and well above any other UK regional centre. The inter-quartile range runs roughly from £290,000 to £680,000, reflecting both higher underlying capital values and a structurally limited supply of cheaper stock. By volume, the typical Cambridge commercial mortgage transaction is a sub-£900,000 SPV acquisition financed at 60% to 70% LTV, with capital values that put many transactions firmly into mid-market commercial mortgage territory.

Sector outlook

Offices and labs in Cambridge are exceptional in the UK regional context. Prime Grade A office space in the central business district and the Cambridge Science Park commands £45 to £55 per square foot, with life-sciences and lab space at the Cambridge Biomedical Campus, Babraham Research Campus and Granta Park commanding £55 to £75 per square foot, the highest non-London rents in the UK. Headline rents have risen materially over the cycle and Grade A vacancy is among the lowest of any UK market. Prime yields of 4.50% to 5.50% on office and 4.25% to 5.00% on lab reflect the structural undersupply and the depth of institutional demand for the use class.

Life sciences is the defining sector. AstraZeneca's global headquarters at the Cambridge Biomedical Campus, alongside Addenbrooke's Hospital and the Wellcome Sanger Institute, anchors the southern campus. Babraham Research Campus and Granta Park host a wider tier of biotech, pharmaceuticals and medical devices occupiers. The Cambridge Innovation Capital and University of Cambridge spin-out pipeline continues to drive a steady flow of expanding occupiers needing new space. Lab supply remains structurally tight and several large-scale developments (including the broader Cambridge Science Park expansion) are in delivery to address the constraint.

Industrial activity within the Cambridge city boundary is limited. Most institutional logistics activity sits along the A14 corridor (Histon, Bar Hill, Newmarket Road) rather than in the city proper. Where it exists, prime industrial in the Cambridge area trades at 5.00% to 6.00% yields, tighter than peer regional cities reflecting last-mile demand for the wider cluster.

Retail in Cambridge is bifurcated. The Grand Arcade and Lion Yard support the central retail offer, with prime rents of £120 to £180 per square foot Zone A. Secondary retail is small as a share of the wider commercial market. Convenience-led retail continues to attract bank lender appetite at 5.50% to 6.50% yields.

Residential investment is meaningfully sized but constrained by capital values. SPV-funded BTL across Romsey, Mill Road and Cherry Hinton delivers yields of 4.50% to 6.50% on stabilised single-let investment, the lowest of any Tier 1 city, reflecting the very high capital values. HMO yields commonly reach 6.00% to 8.00% in the student and visiting-academic belt around the colleges.

Yield environment

The clearest read on real, transacted yields in Cambridge comes from the institutional and public auction markets. Acuitus and Allsop catalogues regularly include Cambridge and wider Cambridgeshire lots across mixed-use, retail and trading-business sales. Recent disclosed yields cluster in the 6.00% to 8.00% band for secondary mixed-use and parade retail, 4.50% to 5.50% for prime office investment with strong covenants, and 4.25% to 5.00% for prime life-sciences and lab stock.

These figures position Cambridge meaningfully tighter than other UK regional markets. Cambridge's prime end trades at yields broadly aligned with outer London life-sciences and lab markets (King's Cross, Stevenage, Oxford), reflecting the depth of institutional capital allocated to the Cambridge cluster. The gap between prime and secondary in Cambridge is narrower than in peer cities, reflecting the depth of buyer competition across the quality spectrum.

Direction of travel through Q4 2025 and Q1 2026 has been broadly stable on yields. Lab and life-sciences rents have continued to firm, supported by the supply constraint, and several new lab developments have been pre-let or pre-Sold.

Lender appetite and risk factors

Cambridge sits in the top tier of UK regional commercial lender competition, with depth of high-street and challenger appetite on prime office, lab and life-sciences stock comparable with outer London. High-street banks (Lloyds, NatWest, Barclays, HSBC, Santander) compete aggressively on prime, with several maintaining East of England regional teams familiar with the Cambridge market. Pricing for the strongest applications sits at 150 to 200 basis points over SONIA, the tightest band of any UK regional centre alongside Reading. Challenger banks (Aldermore, Shawbrook, OakNorth, Allica, Hampshire Trust, Cambridge & Counties) dominate the £500,000 to £8m mid-market. (Cambridge & Counties is locally headquartered and has deep familiarity with the city.)

Specialist lenders cover bridging, refurbishment, lab fit-out finance and value-add situations. Several specialist lenders run dedicated Cambridge focus given the cluster's strategic profile.

For borrowers, principal risks specific to Cambridge in Q2 2026 include: very high capital values which mean LTV-driven debt sizing is the binding constraint on most acquisitions (rather than ICR), planning friction (the city's Green Belt and conservation status materially constrain development), single-tenant concentration risk on some lab and life-sciences assets, and rate-cycle sensitivity on high-value purchases. The structural undersupply of stock supports values but also slows transaction velocity.

Balancing those risks, Cambridge remains one of the most fundable UK commercial markets, and the only regional market where prime lab debt pricing approaches institutional London terms.

Outlook

The 12-month picture for Cambridge commercial property finance through to Q2 2027 is one of continued strength supported by lab supply pipeline delivery and sustained life-sciences occupier demand.

The segments to watch are: Cambridge Biomedical Campus expansion phases, Cambridge Science Park new lab delivery, the Babraham and Granta Park life-sciences clusters, and SPV-acquired BTL across the inner suburbs. Cambridge & Counties Bank's local presence and the city's broader institutional appetite mean lender competition for quality Cambridge income remains intense and supports tight debt pricing relative to other UK regional centres.